NautaDutilh assisted with the cross-border merger between Atai Beckley N.V. and atai Life Sciences Luxembourg S.A., followed by a redomiciliation to the U.S. As part of the transaction, all issued and outstanding ordinary shares of Atai Beckley N.V. were exchanged on a one-for-one basis for newly issued shares of common stock in AtaiBeckley Inc., which continues to trade on NASDAQ under the symbol “ATAI.”
This transaction was a combined effort by our Dutch and Luxembourg offices, working closely with the U.S. team at Latham & Watkins.
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. Its innovative approach aims to address unmet needs in mental health care and improve quality of life for patients worldwide.
Our team was led by Paul van der Bijl, with invaluable contributions from Greet Wilkenhuysen, Hédi Khedache-Thiriet, Max Heuermann, Joppe Schoute, Esther Schreiber, Daphne Smiggels and Leanne Meurs.
